Financial Performance - Total revenue from continuing operations for Q3 fiscal 2025 increased 6% to $1.4 billion compared to $1.3 billion in Q3 fiscal 2024[2] - Net income for Q3 fiscal 2025 was $173.6 million or $1.75 per diluted share, up from $148.4 million or $1.49 per diluted share in Q3 fiscal 2024[3] - Adjusted net income for Q3 fiscal 2025 was $229.1 million or $2.32 per diluted share, compared to $207.6 million or $2.09 per diluted share in the prior year[3] - Healthcare revenue grew 7% to $976.0 million, driven by a 9% increase in consumable revenue and a 13% increase in service revenue[4] - Applied Sterilization Technologies (AST) revenue increased 10% to $258.1 million, with service revenue also growing by 10%[5] - Life Sciences revenue decreased 7% to $136.4 million, primarily due to the divestiture of the CECS business and a decline in capital equipment revenue[6] - Fiscal 2025 revenue outlook updated to approximately 6% growth, down from previous expectations of 6.5% to 7.5%[9] - Adjusted earnings per diluted share for fiscal 2025 is anticipated to be in the range of $9.05 to $9.15, reflecting a ten cent negative impact from currency[9] Cash Flow and Assets - Net cash provided by operations for the first nine months of fiscal 2025 was $887.3 million, compared to $718.5 million in the same period of fiscal 2024[7] - Free cash flow for the first nine months of fiscal 2025 was $588.1 million, up from $457.0 million in the prior year[7] - Free cash flow for the nine months ended December 31, 2024, was $588,104, an increase of 28.7% from $457,013 in 2023[25] - The company reported a free cash flow of $700,000,000 for FY 2025[32] Revenue Breakdown - Revenues for the three months ended December 31, 2024, increased to $1,370,570, a 5.6% rise from $1,297,724 in the same period of 2023[20] - The Healthcare segment generated revenues of $976,044 for the three months ended December 31, 2024, up 6.5% from $916,227 in 2023[23] - Total revenue for the nine months ended December 31, 2024, was $3,978.984 million, with a GAAP growth of 7.0% and organic growth of 6.3%[29] - The total revenue for the Healthcare segment for the nine months ended December 31, 2024, was $2,821.495 million, reflecting an 8.3% growth[29] - The Life Sciences segment had a revenue decline of 4.4% for the nine months ended December 31, 2024, with total revenue of $392.805 million[29] Profitability - Gross profit for the nine months ended December 31, 2024, reached $1,761,553, up 7.7% from $1,635,258 in 2023[20] - The company reported a gross profit of $610.332 million for Q4 2024, compared to $560.026 million in Q4 2023[30] - The company’s gross profit for the nine months ended December 31, 2024, was $650,490,000, compared to $615,784,000 in 2023, reflecting a 5.6% increase[31] Shareholder Returns - Net income attributable to shareholders for the nine months ended December 31, 2024, was $468,969, representing a 23.5% increase compared to $379,616 in 2023[20] - Earnings per share (EPS) for continuing operations increased to $1.76 for the three months ended December 31, 2024, compared to $1.50 in 2023, reflecting a 17.3% growth[20] - Adjusted diluted EPS for Q4 2024 was $2.32, up from $2.09 in Q4 2023[30] - Adjusted net income from continuing operations per diluted share is projected to be between $6.66 and $6.76 for FY 2025[32] - Adjusted net income from continuing operations per diluted share is expected to be between $9.05 and $9.15 for FY 2025[32] Liabilities and Assets - Total current assets decreased to $1,897,853 as of December 31, 2024, down from $2,869,123 as of March 31, 2024[21] - Total liabilities decreased to $3,579,816 as of December 31, 2024, compared to $3,817,249 as of March 31, 2024[21] - Cash and cash equivalents at the end of the period were $155,178, down from $207,020 at the beginning of the period[24] Backlog and Market Presence - The total backlog for continuing operations was $520,000,000, down from $534,433,000 in the previous year[33] - U.S. revenues accounted for 73% of total revenues, amounting to $1,002,586,000 in Q3 FY 2025, compared to $949,957,000 in Q3 FY 2024[33] - The international revenues for Q3 FY 2025 were $343,867,000, slightly up from $328,166,000 in Q3 FY 2024, maintaining 25% of total revenues[33]

Core Insights - STERIS plc reported a 6% increase in total revenue from continuing operations for Q3 fiscal 2025, reaching $1.4 billion compared to $1.3 billion in Q3 fiscal 2024 [1][8] - The company updated its fiscal 2025 outlook, expecting revenue growth of approximately 6%, down from previous expectations of 6.5% to 7.5% due to unfavorable currency rates and lower anticipated capital equipment revenue [7] Financial Performance - Net income for Q3 fiscal 2025 was $173.6 million, or $1.75 per diluted share, up from $148.4 million, or $1.49 per diluted share in Q3 fiscal 2024 [2] - Adjusted net income for Q3 fiscal 2025 was $229.1 million, or $2.32 per diluted share, compared to $207.6 million, or $2.09 per diluted share in the same period last year [2] Segment Performance - Healthcare revenue grew 7% to $976.0 million in Q3 fiscal 2025, driven by a 9% increase in consumable revenue and a 13% rise in service revenue, despite a 5% decline in capital equipment revenue [3] - Applied Sterilization Technologies (AST) revenue increased 10% to $258.1 million, with service revenue also growing by 10% [4] - Life Sciences revenue decreased 7% to $136.4 million, primarily due to the divestiture of the CECS business and a decline in capital equipment revenue, although consumable revenue grew by 14% [5] Cash Flow and Outlook - Net cash provided by operations for the first nine months of fiscal 2025 was $887.3 million, up from $718.5 million in the same period of fiscal 2024 [6] - Free cash flow for the first nine months of fiscal 2025 was $588.1 million, compared to $457.0 million in the prior year [6] - The company anticipates capital expenditures of approximately $360 million and free cash flow of around $700 million for fiscal 2025 [9]

Core Insights - Steris has consistently surpassed earnings estimates, making it a strong candidate for future earnings beats [1][2][3] Earnings Performance - In the last reported quarter, Steris achieved earnings of $2.14 per share, exceeding the Zacks Consensus Estimate of $2.11 per share by 1.42% [2] - In the previous quarter, the company reported earnings of $2.03 per share against an expectation of $2.01 per share, resulting in a surprise of 1% [2] Earnings Estimates - There has been a favorable change in earnings estimates for Steris, with a positive Earnings ESP of +0.57%, indicating bullish sentiment among analysts [3][6] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat [6] Predictive Metrics - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [4] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [5]

Wall Street analysts expect Steris (STE) to post quarterly earnings of $2.32 per share in its upcoming report, which indicates a year-over-year increase of 4.5%. Revenues are expected to be $1.38 billion, down 1.1% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings release, it is of utmost importance to ...

STERIS plc (STE) is expected to release third-quarter fiscal 2025 results on Feb. 6, before market open. Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.14, which beat the Zacks Consensus Estimate by 1.4%. STE beat on earnings in each of the trailing four quarters, delivering an average surprise of 1.18%.STE’s Q3 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $1.38 billion, sugges ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

STERIS’ (STE) new acquisitions and partnerships strengthen its product offerings. Yet macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving STERIS' GrowthSTERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reproce ...

DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9:00 a.m. ET on February 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be ...

DUBLIN, IRELAND, Jan. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced that a jury trial that had been ongoing since December 4, 2024, against Isomedix Operations, Inc. ("Isomedix"), a subsidiary of the Company, ended in a mistrial on January 17, 2025. The case is pending in the Circuit Court of Cook County, Illinois, and involves claims by an individual plaintiff that ethylene oxide emissions from a sterilization facility in Waukegan, Illinois, caused personal ...

STERIS (STE) new acquisitions and partnerships have been strengthening its product offerings. However, macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold).Factors Driving STERIS' GrowthSTERIS frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses. In recent years, the company has made several large acquisitions. It purchased the surgical instrumentation, laparoscopic instrumentation and sterilization container assets f ...